首页> 外文期刊>Pathology International >Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2eu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.
【24h】

Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2eu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.

机译:在HercepTest,Nichirei多克隆抗体,CB11和TAB250检测的乳腺癌HER-2 / neu(c-erbB-2)表达免疫组织化学结果评分中评估观察者之间的一致性。

获取原文
获取原文并翻译 | 示例
           

摘要

To examine interobserver reproducibility in the judgments of HER-2eu (c-erbB-2) oncoprotein expression, HER-2eu expression was scored immunohistochemically. A total of 106 breast carcinomas were independently scored by five or six pathologists, using four commercially available anti-bodies (HercepTest, Nichirei polyclonal antibody, CB11 and TAB250). Two systems were used for the evaluation. In the Dako system, the intensity of membrane staining was primarily evaluated whereas in the Tohoku system, the area of the membrane-staining-positive cells was primarily evaluated. All four antibodies gave excellent concordance rates among the pathologists' judgments of the scores. Using the HercepTest and Nichirei polyclonal antibody, dividing the cases into two groups designated score 3+ and score 0/1+/2+ achieved a higher percentage of concordant cases than division into groups designated score 2+/3+ and score 0/1+. Using the HercepTest, the Dako system tended to achieve higher concordance than the Tohoku system. Conversely, CB11 and TAB250 showed similar concordance rates under both the Dako and the Tohoku systems, regardless of how the cases were divided. High interobserver agreement levels were achieved only when HER-2eu overexpression was defined as a score of 3+, using any of the antibodies; these were similar between the Dako system and the Tohoku system. Positivity by TAB250 was lower than that by CB11. Using the HercepTest and Nichirei polyclonal antibody, cases with a score of 3+ almost always achieved complete interobserver agreement and showed HER-2eu gene amplification. Conversely, cases with a score of 2+ achieved a low percentage of interobserver agreement and showed no gene amplification. Because judgment of a case as score 2+ was not very reproducible, and a score of 3+ was of biological significance and had high interobserver reproducibility, we suggest that only a score of 3+ be considered as overexpression. When cases of score 2+ are entered into a protocol, evaluation should be given bymultiple observers and/or by using other tests such as fluorescence in situ hybridization.
机译:为了检查观察者之间在HER-2 / neu(c-erbB-2)癌蛋白表达判断中的可重复性,对HER-2 / neu表达进行了免疫组织化学评分。由五位或六位病理学家使用四种市售抗体(HercepTest,Nichirei多克隆抗体,CB11和TAB250)对总共106例乳腺癌进行了独立评分。评估使用了两个系统。在Dako系统中,主要评估膜染色的强度,而在Tohoku系统中,主要评估膜染色阳性细胞的面积。在病理学家对分数的判断中,所有四种抗体均给出了极好的一致性。使用HercepTest和Nichirei多克隆抗体,将病例分为指定为得分3+和得分0/1 + / 2 +的两组,比分为指定为得分2 + / 3 +和得分0/1的组获得更高的一致病例百分比+。使用HercepTest,Dako系统趋向于实现比Tohoku系统更高的一致性。相反,无论案件如何划分,在Dako和Tohoku系统下,CB11和TAB250的一致性率都相似。仅当使用任何一种抗体将HER-2 / neu过表达定义为3+时,观察者之间的同意水平才高。这些在Dako系统和Tohoku系统之间是相似的。 TAB250的阳性率低于CB11。使用HercepTest和Nichirei多克隆抗体,得分3+的病例几乎总是达成完整的观察员之间的共识,并表现出HER-2 / neu基因扩增。相反,得分为2+的病例观察者之间达成共识的比例很低,并且没有基因扩增。因为将一个案例判断为2+得分不是很可重复,并且3+得分具有生物学意义并且具有较高的观察者间可重复性,所以我们建议仅将3+得分视为过表达。将2分以上的案例输入实验方案时,应由多个观察员和/或使用其他测试(例如荧光原位杂交)进行评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号